← Leaderboards
Huichun Zhan
Northport Va Medical Center
$3,228,971
Attributed
$3,228,971
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $374.2K · FY2012–25$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,228,971 · 2
VA$0 · 3
By mechanism
R01$3,228,971 · 2
I01$0 · 2
IK2$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionIn VivoMolecularMutationMyeloproliferative DiseaseStem CellsIn VitroCell LineInduced Pluripotent Stem CellHematopoieticHematopoietic Stem CellsCell PhysiologyHematopoiesisCellsMouse ModelPlayGeneticAffectBlood CellsMutantResearch ProposalsHematologic NeoplasmsPeripheral BloodTechnology
Grant awards (21)
Cell Competition in Myeloproliferative Neoplasms$362,298
R01 · FY2025 · CA · contact PI
Endothelial dysfunction in clonal hematopoiesis and its contribution to cardiovascular complications$0
I01 · FY2025 · VA · contact PI
Cell Competition in Myeloproliferative Neoplasms$344,183
R01 · FY2024 · CA · contact PI
Endothelial dysfunction in clonal hematopoiesis and its contribution to cardiovascular complications$0
I01 · FY2024 · VA · contact PI
Cell Competition in Myeloproliferative Neoplasms$356,724
R01 · FY2023 · CA · contact PI
Endothelial dysfunction in clonal hematopoiesis and its contribution to cardiovascular complications$0
I01 · FY2023 · VA · contact PI
Identification of Therapeutic Targets in the Hematopoietic Vascular Niche$0
I01 · FY2023 · VA · contact PI
Cell Competition in Myeloproliferative Neoplasms$374,203
R01 · FY2022 · CA · contact PI
Identification of Therapeutic Targets in the Hematopoietic Vascular Niche$0
I01 · FY2022 · VA · contact PI
Molecular and Cellular Biology of Megakaryocytes in Normal and Neoplastic Hematopoiesis$358,875
R01 · FY2021 · HL · contact PI
Identification of Therapeutic Targets in the Hematopoietic Vascular Niche$0
I01 · FY2021 · VA · contact PI
Molecular and Cellular Biology of Megakaryocytes in Normal and Neoplastic Hematopoiesis$358,875
R01 · FY2020 · HL · contact PI
Identification of Therapeutic Targets in the Hematopoietic Vascular Niche$0
I01 · FY2020 · VA · contact PI
Molecular and Cellular Biology of Megakaryocytes in Normal and Neoplastic Hematopoiesis$358,875
R01 · FY2019 · HL · contact PI
Molecular and Cellular Biology of Megakaryocytes in Normal and Neoplastic Hematopoiesis$358,219
R01 · FY2018 · HL · contact PI
Molecular and Cellular Biology of Megakaryocytes in Normal and Neoplastic Hematopoiesis$356,719
R01 · FY2017 · HL · contact PI
MicroRNA Deregulation in JAK2V617F-positive Chronic Myeloid Neoplasms$0
IK2 · FY2016 · VA · contact PI
MicroRNA Deregulation in JAK2V617F-positive Chronic Myeloid Neoplasms$0
IK2 · FY2015 · VA · contact PI
MicroRNA Deregulation in JAK2V617F-positive Chronic Myeloid Neoplasms$0
IK2 · FY2014 · VA · contact PI
MicroRNA Deregulation in JAK2V617F-positive Chronic Myeloid Neoplasms$0
IK2 · FY2013 · VA · contact PI
MicroRNA Deregulation in JAK2V617F-positive Chronic Myeloid Neoplasms$0
IK2 · FY2012 · VA · contact PI